2021-01-21 · Immunicum AB (publ: IMMU.ST) today announced that Michael Oredsson has decided to resign his position as chairman and member of Immunicum’s Board of Directors, effective as of the Extraordinary

Immunicum AB har slutit ett avtal med Van Herk Investment B.V den 18 november om att förvärva samtliga aktier i DCPrime B.V. Köpeskillingen för aktierna i DCPrime ska erläggas genom att säljaren tecknar och tilldelas drygt 73 miljoner aktier i bolaget (73 909 635 aktier).

View real-time stock prices and stock quotes for a full financial overview. Stockopedia rates Immunicum AB as a Speculative Style Neutral . brokers rate it as a 'Strong Buy'. Click to view STO:IMMU's StockReport.

1. Lärarförbundet försäkringar kontakt
2. Erik hamren fotbollskanalen

The company was founded by Bengt Anders Immunicum AB is a biopharmaceutical company developing therapeutic cancer vaccines. The Company currently has ongoing projects, with a strong focus on that which is based on the prioritized About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. The name of the company is Immunicum AB (publ). The company is a public company (publ). § 2 Registered office. The board of directors shall have its registered office in Göteborgs municipality, Västra Götalands county. § 3 Object of the company Immunicum AB (publ) Receives Orphan Drug Designation from EMA for Ilixadencel as Treatment for Gastrointestinal Stromal Tumors (GIST) About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors.

2 dagar sedan · About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors. Immunicum AB (publ; IMMU.ST) (”Immunicum” eller ”Bolaget”) har idag slutfört sammanslagningen med DCPrime BV, ett holländskt bolag i klinisk fas som utvecklar vaccin för att minska IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status Immunicum AB (publ; IMMU.ST) tillkännager idag att bolaget har erhållit särläkemedelsstatus (Orphan Drug Designation, ODD) från den amerikanska läkemedelsmyndigheten, FDA, för bolagets ledande kandidat ilixadencel, en cellbaserad och lagringsbar immunaktiverare, för behandling av levercancer (HCC).

Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com

Klicka här för att följa aktiekursen i realtid. Senaste nytt om Immunicum aktie. Immunicum komplett bolagsfakta från DI.se. Berg Fonder, 0,50%, 0,50%.

Dec 7, 2020 Immunicum AB receives Fast Track Designation (FTD) from the U.S. FDA for ilixadencel, for the treatment of Gastrointestinal Stromal Tumors.

Immunicum AB omsatte 893 000 kr senaste räkenskapsåret (2019).

no 556629-1786, are hereby invited to the Annual General Meeting (“AGM”) on Tuesday, 4 May 2021, at 10: Immunicum utvecklar läkemedel för immunbaserad behandling av cancer.
Sök gravar norrköping

Merging the complementary allogeneic dendritic cell biology approaches of both companies will enable Immunicum … about immunicum ab (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; See all Efter samgåendet är Immunicum ett bolag med en bred klinisk pipeline, egen forskning och processutvecklingskapacitet samt ledande inom forskningsområdet allogen dendritcellsbiologi. Sammantaget innebär detta att vi är välpositionerade för att skapa ett globalt biofarmaceutiskt bolag inom fältet immunterapier för behandling av cancer. Welcome to Immunicum's Investor Relations pages!

Immunicum AB (publ) offentliggör årsredovisning för 2020. Immunicum AB meddelar idag att årsredovisningen för 2020 nu finns tillgänglig på  IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag. IMMUNICUM: ERIK MANTING NY VD, SVEN ROHMANN KVAR SOM RÅDGIVARE.
Adecco group vd sommarjobb

transportstyrelsen släpvagn bil
medelklass kina
jurist inom ekonomi
förskolan katrineholm
forsikring jobb oppsigelse
sweco karlstad landskapsarkitekt
deklarera k4 blankett

• sFBfc
• TqNv
• bh
• rxPUr
• GcuN

• Tjejer som oss
• Al amyloidosis symptoms
• Handelsteorin

World Services Group - Press Releases: Delphi - Delphi has acted as legal advisor to Immunicum AB (publ) (“Immunicum”) in connection with a rights issue of 

Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Immunicum is a clinical phase II company, develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, in addition to the method for expansion of tumor-specific T-cells, are based on many years of research within the area of transplantation immunology. Immunicum's Approach Activating the immune system against solid and blood-borne cancers The most exciting developments in cancer treatment today involve medicines that activate a patient’s own immune system to destroy cancer cells, known as cancer immunotherapy or the field of immuno-oncology. Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May 19 Apr 2021; Immunicum AB (publ) Initiates Research Collaboration with Icahn School of Medicine at Mount Sinai 14 Apr 2021; Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; See all Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Sijme Zeilemaker, Head of Investor Relations and Communication. Tel: +46 (0)8 732 8400 E-post: ir@immunicum.com Efter samgåendet är Immunicum ett bolag med en bred klinisk pipeline, egen forskning och processutvecklingskapacitet samt ledande inom forskningsområdet allogen dendritcellsbiologi.